XML 54 R34.htm IDEA: XBRL DOCUMENT
v3.22.2

Segment Information (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2022
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | The following table presents revenue for each reportable segment and Corporate:
(in millions) | 2022 |  | 2021 |  | 2020
Pharmaceutical | $ | 165,491 |  |  | $ | 145,796 |  |  | $ | 137,495 |
Medical | 15,887 |  |  | 16,687 |  |  | 15,444 |
Total segment revenue | 181,378 |  |  | 162,483 |  |  | 152,939 |
Corporate (1) | (14) |  |  | (16) |  |  | (17) |
Total revenue | $ | 181,364 |  |  | $ | 162,467 |  |  | $ | 152,922 |
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue by Reportable Segment | The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:
(in millions) | 2022 |  | 2021 |  | 2020
Pharmaceutical Distribution and Specialty Solutions (1) (2) | $ | 164,580 |  |  | $ | 144,988 |  |  | $ | 136,693 |
Nuclear and Precision Health Solutions | 911 |  |  | 808 |  |  | 802 |
Pharmaceutical segment revenue | 165,491 |  |  | 145,796 |  |  | 137,495 |
Medical distribution and products (3) | 13,462 |  |  | 14,485 |  |  | 13,429 |
Cardinal Health at-Home Solutions | 2,425 |  |  | 2,202 |  |  | 2,015 |
Medical segment revenue | 15,887 |  |  | 16,687 |  |  | 15,444 |
Total segment revenue | 181,378 |  |  | 162,483 |  |  | 152,939 |
Corporate (4) | (14) |  |  | (16) |  |  | (17) |
Total revenue | $ | 181,364 |  |  | $ | 162,467 |  |  | $ | 152,922 |
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services". (2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division. (4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Disaggregation of Revenue [Table Text Block] |
(in millions) | 2022 |  | 2021 |  | 2020
Pharmaceutical Distribution and Specialty Solutions (1) (2) | $ | 164,580 |  |  | $ | 144,988 |  |  | $ | 136,693 |
Nuclear and Precision Health Solutions | 911 |  |  | 808 |  |  | 802 |
Pharmaceutical segment revenue | 165,491 |  |  | 145,796 |  |  | 137,495 |
Medical distribution and products (3) | 13,462 |  |  | 14,485 |  |  | 13,429 |
Cardinal Health at-Home Solutions | 2,425 |  |  | 2,202 |  |  | 2,015 |
Medical segment revenue | 15,887 |  |  | 16,687 |  |  | 15,444 |
Total segment revenue | 181,378 |  |  | 162,483 |  |  | 152,939 |
Corporate (4) | (14) |  |  | (16) |  |  | (17) |
Total revenue | $ | 181,364 |  |  | $ | 162,467 |  |  | $ | 152,922 |
(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services". (2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division. (4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block] | The following table presents revenue by geographic area:
(in millions) | 2022 |  | 2021 |  | 2020
United States | $ | 176,855 |  |  | $ | 157,756 |  |  | $ | 148,707 |
International | 4,523 |  |  | 4,727 |  |  | 4,232 |
Total segment revenue | 181,378 |  |  | 162,483 |  |  | 152,939 |
Corporate (1) | (14) |  |  | (16) |  |  | (17) |
Total revenue | $ | 181,364 |  |  | $ | 162,467 |  |  | $ | 152,922 |
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment | The following tables present segment profit by reportable segment and Corporate:
(in millions) | 2022 |  | 2021 |  | 2020
Pharmaceutical | $ | 1,770 |  |  | $ | 1,684 |  |  | $ | 1,753 |
Medical | 216 |  |  | 577 |  |  | 663 |
Total segment profit | 1,986 |  |  | 2,261 |  |  | 2,416 |
Corporate | (2,582) |  |  | (1,789) |  |  | (6,514) |
Total operating earnings/(loss) | $ | (596) |  |  | $ | 472 |  |  | $ | (4,098) |
Depreciation and Amortization and Additions to Property and Equipment by Reportable Segment | The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate:
(in millions) | 2022 |  | 2021 |  | 2020
Pharmaceutical | $ | 193 |  |  | $ | 151 |  |  | $ | 135 |
Medical | 216 |  |  | 226 |  |  | 243 |
Corporate | 283 |  |  | 406 |  |  | 535 |
Total depreciation and amortization | $ | 692 |  |  | $ | 783 |  |  | $ | 913 |
(in millions) | 2022 |  | 2021 |  | 2020
Pharmaceutical | $ | 79 |  |  | $ | 55 |  |  | $ | 47 |
Medical | 140 |  |  | 97 |  |  | 86 |
Corporate | 168 |  |  | 248 |  |  | 242 |
Total additions to property and equipment | $ | 387 |  |  | $ | 400 |  |  | $ | 375 |
Assets by Reportable Segment | The following table presents total assets for each reportable segment and Corporate at June 30:
(in millions) | 2022 |  | 2021 |  | 2020
Pharmaceutical | $ | 26,409 |  |  | $ | 23,624 |  |  | $ | 22,398 |
Medical (1) | 11,632 |  |  | 15,408 |  |  | 14,691 |
Corporate | 5,837 |  |  | 5,421 |  |  | 3,677 |
Total assets | $ | 43,878 |  |  | $ | 44,453 |  |  | $ | 40,766 |
(1) Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.
Property and Equipment, Net by Geographic Area | The following tables present property and equipment, net by geographic area:
(in millions) | 2022 |  | 2021 |  | 2020
United States | $ | 1,976 |  |  | $ | 1,958 |  |  | $ | 1,880 |
International | 385 |  |  | 402 |  |  | 486 |
Property and equipment, net | $ | 2,361 |  |  | $ | 2,360 |  |  | $ | 2,366 |

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph b -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 + Details
Name: | us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration